MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Mar 19, 2025 · CIK: 1878313

Sentiment: neutral

Topics: corporate-filing, sec-filing

TL;DR

MAIA Bio filed an 8-K on 3/19/25, standard corporate update.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on March 19, 2025, reporting other events and financial statements. The filing details the company's incorporation in Delaware, its principal executive offices in Chicago, IL, and its standard industrial classification in Pharmaceutical Preparations.

Why It Matters

This filing provides an official update on MAIA Biotechnology's corporate and financial reporting status with the SEC.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no immediate financial or operational news.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 19, 2025.

When was MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. was incorporated in Delaware.

What is the company's principal executive office address?

The company's principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

What is MAIA Biotechnology's Standard Industrial Classification code?

MAIA Biotechnology's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for MAIA Biotechnology?

The SEC file number for MAIA Biotechnology, Inc. is 001-41455.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 19, 2025 regarding MAIA Biotechnology, Inc. (MAIA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing